EUCTR2021-006861-39-DE招募中1 期
A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode(GH001-BD-202)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •4. Has a body mass index (BMI) in the range of 18.5 and 40 kg/m2 (inclusive) at screening.
- •5. Meets the trial criteria for bipolar II disorder and is experiencing a major depressive episode, as assessed by a trial psychiatrist or registered clinical psychologist:
- •-Meets the DSM-5 diagnostic criteria for bipolar II disorder with a current major depressive episode confirmed by the Mini-International Neuropsychiatric Interview (MINI) v7.0.2 -Has a Montgomery-Asberg Depression Rating Scale (MADRS) total score of = 24 at screening and prior to first dose on Day 0
- •8.Female patients must be either surgically sterile (hysterectomy, tubal ligation, or bilateral oophorectomy) or postmenopausal with amenorrhea for the last 2 years or remain completely abstinent (complete avoidance of heterosexual intercourse) or use a highly effective (failure rate <1%) medically accepted contraceptive method, including, but not limited to, hormone contraceptives that inhibit ovulation, intrauterine device (including hormone-releasing intrauterine device/systems) for 30 days before and 90 days after GH001 dosing and must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the pre-test day (Day -1).
- •10.Is able to inhale 3 liters of air from the test balloon within a single breath at screening, on the pre-test day (Day -1) and prior to first dose (Day 0). An incentive spirometer will be given to patients following screening. They will be encouraged to practice deep inhalations prior to the first dose on the test day (Day 0). Patients failing the test inhalation at screening may have the test inhalations repeated within 14 days of the original screening date.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •2. Has, based on history, psychiatric assessment, and evaluation of the MINI, a current or prior diagnosis of bipolar I disorder, a manic episode, a psychotic disorder, major depressive disorder (MDD) or other mood disorder with psychotic features, obsessive compulsive disorder, post-traumatic stress disorder (PTSD), autism spectrum disorder, borderline personality disorder, schizophrenia, delusional disorder, paranoid personality disorder, schizoaffective disorder, clinically significant intellectual disability, or any other psychiatric comorbidity that renders the patient unsuitable for the trial according to the investigator’s judgment.
- •3. Has one or more first degree relatives with a current or previously diagnosed psychotic disorder, bipolar I disorder, or MDD with psychotic features.
- •4. Has significant suicide risk as defined by:
- •(a) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, during the screening period, or at Baseline; or
- •(b) suicidal behaviors within the past year; or
- •(c) clinical assessment of significant suicidal risk during clinical interview; or
- •(d) non-suicidal self-injury within the past year.
- •6. Has taken anti-depressive medication e.g., a selective serotonin reuptake inhibitor (SSRI) such as paroxetine, fluoxetine (including in combination with olanzapine) or citalopram, a serotonin and norepinephrine reuptake inhibitor (SNRI) such as venlafaxine or duloxetine, a tricyclic antidepressant (TCA) such as amitriptyline or imipramine, an antipsychotic such as quetiapine, an atypical antidepressant such as bupropion or vortioxetine, or an N-methyl-D-aspartate (NMDA) receptor antagonist such as esketamine, within 7 days or 5 half-lives (whichever is longer) prior to dosing (exception: within the last 5 weeks in the case of fluoxetine).
- •Patients who at screening are on such medication and are willing to discontinue and observe a wash-out period of 7 days or 5 half-lives (whichever is longer) prior to GH001 dosing (5 weeks for fluoxetine), can still be included, but the wash-out must be implemented, completed and documented before study drug administration. Gradual dose reduction before discontinuation and wash-out should be performed as per the investigator’s judgement and applicable medical guidelines.
- •To ascertain patient safety during the potential taper and washout of anti-depressive medication, patients undergoing such taper and washout will be contacted weekly by the site.
- •8. Is taking mood stabilizer therapy other than lamotrigine at screening or is, by the investigator, considered to be in the need of mood stabilizer treatment other than lamotrigine during the study.
- •A period of at least 6 months without receipt of Lithium or Valproate and without an occurrence of a hypomanic episode is required prior to dosing.
- •A period of at least 2 weeks or 5 half-lives (whichever is longer) without receipt of atypical anti-psychotics (e.g., aripiprazole, olanzapine, risperidone) and without an occurrence of a hypomanic episode is required prior to dosing.
- •18.Has any current or past clinically significant condition (e.g., severe infection, severe pulmonary disease, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, severe hepatic or renal failure, severe brain disorder (including seizure disorder, stroke, dementia, degenerative neurologic diseases, meningitis, encephalitis, and head injury with loss of consciousness) that may interfere with the interpretation of t
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive EpisodeBipolar II DisorderMedDRA version: 26.1Level: HLGTClassification code 10026753Term: Manic and bipolar mood disorders and disturbancesSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2021-006861-39-NLGH Research Ireland Limited15
招募中
1 期
A phase 2 clinical trial of GH001 in patients with postpartum depressioEUCTR2021-006879-42-NLGH Research Ireland Limited15
进行中（未招募）
1 期
Phase 1/2 study of GH001 in depressioTreatment-resistant depressionEUCTR2018-004208-20-NLGh Research Limited16
招募中
1 期
HM-001-CT1 StudyJPRN-jRCT2051230033Kawashima Atsunari48
已完成
2 期
Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstructioJPRN-UMIN000003298Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University20